Jefferies Raises Price Target On Regeneron Pharma (REGN) to $111

Jefferies boosted its price target on Regeneron Pharma (NASDAQ: REGN) from $75 to $111 and reiterated its Buy rating following in-line Bascom-Palmer data.

The firm comments, "2-yr VIEW data at Bascom-Palmer were generally in-line with our expectations with expert commentaries on Eylea’s outlook in AMD and also consistent with our assumptions and recent survey results anticipating meaningful Eylea mkt share gains. We are increasing our PT to $111 from $75 largely on increased DME sales ests driven by increased adoption."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $96.86 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cummins (CMI) PT Lowered to $675 at Jefferies
• Benchmark Reiterates Buy Rating on NVIDIA (NVDA), Updates Estimates
• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results